Program
pimasertib
Also written as “Pimasertib”, “MSC1936369B” and “Pimasertib Capsule (Part A)”.
Its studies are mostly in Neoplasms · Melanoma · Neoplasm Metastasis · Ovarian Neoplasms · Carcinoma, Hepatocellular, led by 3 companies.
Drug pagePimasertib: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck KGaA, Darmstadt, Germanyits history only | 110 open or running | phase 2since Aug 11, 2009 | Aug 11, 2009 | none ahead |
| Day One Biopharmaceuticals | 10 open or running | phase 1since Jul 3, 2025 | Jul 3, 2025 | none ahead |
| Sanofiits history only | 10 open or running | phase 1since May 16, 2011 | May 16, 2011 | none ahead |
Also a collaborator on its studies: Merck Serono S.A., Geneva and Merck Serono Co., Ltd., Japan.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Day One Biopharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 3, 2025First study: phase 1 study in MelanomaFirst studyNCT07121829 · 44 enrolled · United States, Canada
TargetBeta
“An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) ”NCIt, by rule
“Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cobimetinibrule | Hoffmann-La Roche | phase 3 | 38 |
| mirdametinibrule | Merck KGaA, Darmstadt, Germany | phase 2 | 9 |
| polfurmetinib | Pfizer | phase 1 | 3 |
Studies
The one study Day One Biopharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07121829Melanoma · United States, Canada | 1 | Terminated | Dec 18, 2024 | 44 |
How it is read
Names in the registry
- “Pimasertib”, 16 entries
- “MSC1936369B”, 5 entries
- “Pimasertib Capsule (Part A)”, 2 entries
- “Pimasertib Tablet (Part A)”, 2 entries
- “MSC1936369B (pimasertib)”, 2 entries
Conditions, from the studies’ own filings
- Neoplasms, 5 studies
- Melanoma, 2 studies
- Neoplasm Metastasis, 2 studies
- Ovarian Neoplasms, 1 study
- Carcinoma, Hepatocellular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.